We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vernalis | LSE:VER | London | Ordinary Share | GB00B3Y5L754 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.17 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
08/9/2015 07:27 | The lack of interest in this share is v surprising. I've just topped up with this good news. | investordave | |
08/9/2015 06:52 | Bang on time for the 2015 cold and cough season. Just the tonic we need! | fhmktg | |
14/8/2015 10:02 | Well done if you bought. If you sold, I think you may regret it in the mid to long term. | investordave | |
13/8/2015 19:43 | That's why I didn't say. It still doesn't show today - I guess my broker goes through a clearing house. | gbb483 | |
13/8/2015 09:07 | gbb483 - Buy or sell if you don't mind me asking? | investordave | |
12/8/2015 17:45 | Strange, I traded these today but the trade hasn't appeared on the list. | gbb483 | |
11/8/2015 16:43 | Untold joy!!! At last, patience rewarded! dum spiro spero. | fhmktg | |
11/8/2015 15:31 | Vernalis (VER + ), a UK biotech business focused on cough and cold treatments, was one of the fund's top performers. Shares in the company have jumped nearly 60% after the approval of Tuzitra, its first cough-cold product, in April. 'Investors continue to significantly undervalue the potential of Vernalis' cough cold franchise,' said Woodford. | twodegrees | |
11/8/2015 15:29 | woodhouse yippee | twodegrees | |
11/8/2015 14:58 | Vernalis is preparing for commercial launch of Tuzistra XR, its extended-release, codeine-based cough cold treatment following FDA approval in April. The product has greater commercial potential than previously anticipated with an addressable market of up to £1.8bn and is the only approved codeine-based, long-release liquid treatment. We forecast maiden cough cold sales in FY16 leading to profitability in FY18. We increase our valuation from £323m to £406m. Year end Revenue (£m) PBT* (£m) EPS* (p) DPS (p) P/E (x) Yield (%) 12/12 14.6 (2.7) (0.8) 0.0 N/A N/A 12/13 14.1 (4.7) (0.8) 0.0 N/A N/A 06/15e 18.9 (13.1) (1.8) 0.0 N/A N/A 06/16e 17.7 (21.3) (4.2) 0.0 N/A N/A Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments and FX gains/losses on cash holdings. FDA approval of Tuzistra XR Tuzistra XR, a 12-hourly dosed or extended-release (ER) liquid narcotic cough cold treatment was FDA approved on 30 April. Tuzistra XR is indicated for the relief of cough and symptoms associated with respiratory tract allergies and common cold. Its active ingredients, disclosed at the time of the FDA approval, are codeine, a cough suppressant and chlorpheniramine, an antihistamine. Its primary market, the codeine plus antihistamines segment, has an estimated value of £510m at current net brand pricing, although Tuzistra XR has potential in other market segments. Commercial potential in expanded markets Tuzistra XR has additional potential among all codeine cough cold prescribers, a c $1.2bn market, including codeine plus expectorant products. Furthermore, DEA reclassification in 2014 of hydrocodone-based cough cold products from Schedule III into the more restrictive Schedule II could drive Tuzistra XR sales into the $550m hydrocodone segment. Vernalis has a pipeline of four ER products, providing further commercial potential in the c $3.3bn prescription cough cold market. Maiden cough cold revenues forecast in FY16 We have increased our FY15 sales estimate from £18.4m to £18.9m, adding in a £0.5m research milestone payment. We have lowered our FY16 sales estimate from £18.3 to £17.7m, with greater caution on cough cold sales in launch year, but we increase our peak sales estimate for Tuzistra XR to $240m from $120m, c 13% of the addressable cough cold market. Our end-2015 net cash estimate is £54.6m, which we forecast is sufficient to fund Vernalis through to profitability in 2018. | twodegrees | |
11/8/2015 14:57 | Equity Research (VER) edison investment research Vernalis plc Vernalis - Tuzistra Xr; Us Commercial Potential Unveiled 17/06/2015 | twodegrees | |
11/8/2015 14:55 | 10,000 at 81.86 and it is an ordinary trade...as you say investor dave...something is brewing. and I am glad I did not bail out. | twodegrees | |
11/8/2015 14:53 | a few weeks back some decent large buys happened, I think woodhouse, if I remember has taken a position and other news suggested that the value of shares should be more than £1. Apologies if I have given the wrong information re name above...but certainly it was done | twodegrees | |
11/8/2015 14:16 | The question is why is the share price ticking up. Clearly something is going on that we mere mortals don't know about. | investordave | |
11/8/2015 13:57 | December 2009 was £1.05 , I think it will surpass that price this time | twodegrees | |
11/8/2015 13:56 | I have just got back all my loses for the last 5 years at this price... | twodegrees | |
11/8/2015 13:07 | Something brewing folks? | investordave | |
06/8/2015 15:15 | so no RNS but still keeps ticking up nicely, I had a £6k loss at one point and quickly making that up. | twodegrees | |
05/8/2015 15:47 | Even if it was a 'sell' the interesting question is Who? was the buyer... If it was a buy then who was the seller ? Perhaps an RNS one way or the other might be on its way. | rosejs2 | |
05/8/2015 15:38 | Was that a big sell or buy after hours today? It looks like a sell given the closing price although I hope not. | investordave | |
31/7/2015 06:47 | Two degrees. Long may it continue. | investordave | |
24/7/2015 15:31 | this keeps moving higher, nice and steady | twodegrees | |
17/6/2015 04:41 | Vernalis plc (LON:VER)‘s stock had its “buy” rating reiterated by equities research analysts at Stifel Nicolaus in a research note issued to investors on Thursday. They currently have a GBX 103 ($1.57) target price on the stock. Stifel Nicolaus’ target price points to a potential upside of 41.58% from the company’s current price. Vernalis plc (LON:VER) opened at 72.5500 on Thursday. Vernalis plc has a 52 week low of GBX 30.7500 and a 52 week high of GBX 74.5750. The stock has a 50-day moving average of GBX 62.20 and a 200-day moving average of GBX 51.91. The company’s market cap is £320.90 million. Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating and set a GBX 92 ($1.40) price target on shares of Vernalis plc in a research note on Thursday. Separately, analysts at N+1 Singer reiterated a “buy” rating and set a GBX 87 ($1.33) price target on shares of Vernalis plc in a research note on Friday, May 1st. Vernalis plc is a United Kingdom-based research and development-stage pharmaceutical company. Vernalis has one marketed product and a portfolio of development and drug discovery programmes. Vernalis has nine active collaborations, four covering programmes in pre-clinical through to Phase II development and four active drug discovery collaborations. | twodegrees | |
12/6/2015 15:42 | It's that man again- Mr W now over 21%! Statement of confidence if ever I heard one! Onwards and upwards! | fhmktg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions